Thank you, Tricia. I'm excited share our progress so far in 2023. But to begin, I'd like to take a step back and remind you why we're here at GeneDx. Over the past decade, we've seen a massive conversion from single-gene testing to multi-gene panels. GeneDx has played an instrumental role in ushering in this new era, while also pioneering an even more comprehensive set of services with whole exome and whole genome testing. With more data supporting the clinical necessity of exome sequencing versus multi-gene panels, GeneDx is now poised to lead this conversion to deliver more comprehensive, more definitive answers to more patients. Today, we're focused on rare disease testing and the pediatric setting. With the current standard of care is generally a lack of testing, usually resulting in a multiyear diagnostic odyssey for children and for their parents. In fact on average, it takes eight years to diagnose a rare disease. We know that exome and genome testing, dramatically shortens that timeframe from years to weeks. And we also know that these pediatric-rare diseases are not at all rare when taken as a whole. Think of how cancer is actually a constellation of hundreds of diseases. Similarly, there are 7,000 rare diseases that together are nearly as common as cancer. Consider that one in eight women will be diagnosed with breast cancer. Of one in 10 people have a rare disease half of, whom are children. In fact, we estimate that each year over one million infants and children in the U.S. alone would benefit from whole exome or genome testing. And fortunately, we're not alone in our mission to expand care. Medical societies, such as ACMG, NSGC and the American Epilepsy Society are calling for exome and genome sequencing as a first-line test and major national payers are moving to cover highly validated whole exome and/or whole genome testing, given the costly alternative. Of the 450,000 exomes GeneDx has tested over the past decade a quarter of them have been completed in just the past year. Momentum is building. As we look to the future, we expect that whole exome and genome tests will become increasingly standard of care for patients with broader diseases such as, cardiovascular and neurodegenerative disease allowing us to expand into the adult population. But today, job number one is expanding the utilization of our services, primarily in pediatric testing with an emphasis on converting physicians' use of exome as well as panel tests that serve as stepping stones to exome testing. So let's dive into our 2023 progress. I am pleased to say that, we've generated over $40 million in revenue in the first quarter of 2023. We saw increased volume across all of our testing coming in at nearly 53,000 tests this quarter, giving us confidence that the market is growing. And patients and physicians are turning to genetic testing and GeneDx more and more. The growth in all test lines from Q4 to Q1 gives us the conviction that the strategy is working, and these volume gains will materialize into revenue growth. Furthermore, our focus on accelerating the use of the exome is working. Our progress is reflected in the robust increase of volume and revenues of full exome and genome test, which delivered $22.4 million of the $40 million in revenue, representing a 22% increase in whole exome revenues year-over-year in the first quarter. We continue to see the momentum of growth in our exome volume and revenue in April, and we expect to see margin expansion throughout the course of this year as these tests deliver a gross margin of approximately 60%. Given the time frame from ordering to revenue recognition, we expect to see revenue and gross margin shift in the second quarter results and build towards a significant amount of growth in the second half of this year. There are five factors that will enable this acceleration. First, we're continuing to strengthen our commercial footprint and strategy. Our team is focused on converting physicians to tests that are better for patients and better for our business. This includes the increased volume of certain non-exome tests that are strategically important as physicians become comfortable with broader genetic testing. We see them as stepping stones to exome. We are educating clinicians that exome testing provides a higher diagnostic yield compared to tests like CMA, FMR1, and multi-gene panels, which leave many patients behind. We're also targeting nongenetics, who may be new to genetic diagnostics. We're encouraged by data that show that 30% of physicians who ordered their first exome GeneDx in Q1 were new customers to GeneDx. And orders among neurologists and pediatric specialists were significantly higher compared to last year. We've taken the first part of the year to continue to invest in our commercial team. We expanded sales territories from 58 to 66 across the United States and also added dedicated cross-functional teammates for each sales rep to support growth. That includes medical science Leason, client relationship managers, and our managed care team. We've also built our incentive plans to drive the conversion of orders from panel test to exome sequencing. Second, in our acceleration is marketing. Our team is focused on meeting the clinician where they are in and outside of the clinic. We're talking to them at conferences, generating data through publications, increasing brand awareness efforts, and launching a variety of initiatives in Q1 to aid in education, engagement and ultimately build share and accelerate growth. Our cross-channel activities drive awareness through advertising, e-mail campaigns and social media presence bringing brand recognition to GeneDx's offerings and differentiation from others as we build and expand the market. And in fact, we've doubled traffic to our website since Q4 of 2022, and we expect to continue to build on that. Third, we're continuing to contribute to clinical research, which is also providing insightful data into the value of exome sequencing for patients. We recently presented new data at the ACMG Annual Meeting, which demonstrated the diagnostic advantages of exome sequencing over chromosomal microarray or CMA. And the poster, we compared recorded copy number variants or CNVs, on more than 8,000 patients who had CMA and exome sequencing and showed that exome sequencing as a much higher diagnostic yield as it covers both sequence variance in CNVs, where CMA is limited to detecting only CNV. CMA is a commonly used test that is a current standard of care driven by outdated guidelines and these critical data presented at ACMG are guiding our conversations to convince clinicians why they should order exome first. Sharing less research and driving adoption takes time. Fourth is our focus on product improvement to improve our customer experience and operating efficiency. We've been working to automate and shorten our turnaround time to facilitate quicker results for patients with the same high quality. Automation is also key to decreasing our COGS and expanded gross margins. We've also introduced Buckle swab collection for genome sequencing, including our rapid testing option, which enables easier collection of parental or relative samples for Trio testing, which has been shown to increase the diagnosis rate by nearly double. The fifth factor goes beyond our own efforts. Our work is amplified by medical societies and in particular, payers who are taking notice of the favorable clinical and health-economic benefits of exome and genome sequencing. Both UnitedHealthcare and Cigna have adopted favorable coverage of genome sequencing recently and we are working with physicians to be sure they are aware of these policy changes. Recently, state coverage groups are continuing to make meaningful progress. North Carolina Medicaid published an updated clinical coverage policy to add coverage for exome sequencing and outpatient setting becoming the 28th state to do so. One of the many key barriers to the adoption of testing is what to do with the results. For so many, getting an answer as a relief. And we're committed to going a step further by working with a broader ecosystem of biopharma, payers and advocacy groups to help connect patients to the best possible treatment for them. Our opportunity to partner with biopharma is significant. We're seeing deal flow generated across various therapeutic areas based on the clinical and genomic data assets, which are part of our Centrella platform. In the first quarter, we signed data agreements with five companies focused on rare diseases or neurological disorders, including forming groups. We also launched a new Centralis product called Data Explorer, which helps our internal teams more efficiently gather data and deliver these opportunities. We believe these agreements are highly scalable and have high gross margins with high value to our partners and patients as well. With strong performance year-to-date we're on our way to reach profitability in 2025. We're clearly in an exciting moment in health care to accelerate the delivery of personalized and actionable health insights to inform diagnosis direct treatment and improve drug discovery and development. And with that, I'd like to pass the call to Kevin.